Clinical Research

Cardioneural ablation provides a new treatment option for vasovagal syncope
The procedure is designed to help patients who experience frequent fainting episodes that impair their quality of life.
EARLY TAVR update: New data highlight continued benefits of treating asymptomatic aortic stenosis
Philippe Généreux, MD, presented updated findings from one of cardiology's most closely watched trials at New York Valves 2026.
Shockwave Medical announces new studies evaluating carotid IVL platform
Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease.
TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data
All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in JSCAI.
Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis
TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to conduct a pivotal clinical trial for TRiCares Topaz transcatheter tricuspid valve replacement (TTVR) system in the U.S. The TTVR system uses two stent frames, one for the valve and one to engage the annulus with a membrane shirt between them to enable flexing of the outer ring to better seal against regurgitation.expansing stents

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system

The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.

Screening and treatment for chronic kidney disease in heart disease patients needs to be expanded

The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Around the web

Radiology Business

Experts raise concern about high cost-sharing for imaging in some Medicare Advantage plans

Radiology Business

Homeland Security warns of vulnerabilities in medical imaging software

Clinical Research

Cardioneural ablation provides a new treatment option for vasovagal syncope

EARLY TAVR update: New data highlight continued benefits of treating asymptomatic aortic stenosis

Shockwave Medical announces new studies evaluating carotid IVL platform

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data

Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis

Around the web